Cite
HARVARD Citation
Zhang, P. et al. (n.d.). Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial. Lancet oncology. 18 (3), pp. 371-383. [Online].